TCGLS offers a comprehensive suite of PROTAC (PROteolysis TArgeting Chimeras) and MG (molecular glue) chemistry services backed by over a decade of focused experience in the design, synthesis, and optimization of these degraders. Our TPD (targeted protein degrader) platform leverages 25+ years of expertise in integrated drug discovery to support the evolving needs of global biotech and pharmaceutical partners.
Proven Track Record in PROTAC and MG Capability Development
With years of specialized PROTAC and MG chemistry expertise, TCGLS is continually and successfully delivering a wide range of PROTAC molecules and MGs —from milligram to multigram scale—across multiple collaborative programs. Our team has supported the synthesis of over 3000-membered PROTAC libraries, contributing to leads currently advancing through clinical trials.
Our Core Capabilities
Why Partner with TCGLS?
25+ years in small molecule drug discovery and CRO services
Proven track record in delivering lead compounds that have progressed to advanced clinical stages
Novel TPD design supported by CADD to accelerate rational degrader development
Rapid analogue generation using in-house inventory of ligand–linker conjugates
Scalable synthesis from milligram to multigram with PR&D support
Integrated biology services including in vitro pharmacology, ADME-PK screening
Agile operations enabling customised PROTAC libraries with rapid turnaround
Deep knowledge of TPD landscape and emerging modalities (AUTCs, ATTECs, ADCs)